AAAAAA
Results: 76-100/1162
Authors:
Strom, SS
Spitz, MR
Yamamura, Y
Babaian, RJ
Scardino, PT
Wei, QY
Citation: Ss. Strom et al., Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: A case-control study, PROSTATE, 47(4), 2001, pp. 269-275
Authors:
Tieva, A
Stattin, P
Wikstrom, P
Bergh, A
Damber, JE
Citation: A. Tieva et al., Gonadotropin-releasing hormone receptor expression in the human prostate, PROSTATE, 47(4), 2001, pp. 276-284
Authors:
Juarranz, MG
Bodega, G
Prieto, JC
Guijarro, LG
Citation: Mg. Juarranz et al., Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation, PROSTATE, 47(4), 2001, pp. 285-292
Authors:
Dorai, T
Cao, YC
Dorai, B
Buttyan, R
Katz, AE
Citation: T. Dorai et al., Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo, PROSTATE, 47(4), 2001, pp. 293-303
Authors:
Huang, JK
Jan, CR
Citation: Jk. Huang et Cr. Jan, Mechanism of estrogens-induced increases in intracellular Ca2+ in PC3 human prostate cancer cells, PROSTATE, 47(3), 2001, pp. 141-148
Authors:
Leav, I
Schelling, KH
Adams, JY
Merk, GB
Alroy, J
Citation: I. Leav et al., Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma, PROSTATE, 47(3), 2001, pp. 149-163
Authors:
Pisters, LL
Wang, XH
Chung, LWK
Hsieh, JT
Citation: Ll. Pisters et al., Differential expression of c-erb B2/neu, epidermal growth factor receptor,cytokeratin 8, and the prostatic steroid-binding protein gene in rat ventral prostate during postnatal development, PROSTATE, 47(3), 2001, pp. 164-171
Authors:
Mai, KT
Yazdi, HM
Farmer, J
Citation: Kt. Mai et al., Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: Evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitionalcell carcinoma, PROSTATE, 47(3), 2001, pp. 172-182
Authors:
O'Neill, AJ
Boran, SA
O'Keane, C
Coffey, RNT
Hegarty, NJ
Hegarty, P
Gaffney, EF
Fitzpatrick, JM
Watson, RWG
Citation: Aj. O'Neill et al., Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma, PROSTATE, 47(3), 2001, pp. 183-188
Authors:
Corvin, S
Strasser, H
Boesch, ST
Bartsch, G
Klocker, H
Citation: S. Corvin et al., Human rhabdosphincter cell culture: A model for videomicroscopy of cell contractions, PROSTATE, 47(3), 2001, pp. 189-193
Authors:
Taj, MM
Tawil, RJ
Engstrom, LD
Zeng, Z
Hwang, C
Sanda, MG
Wechsler, DS
Citation: Mm. Taj et al., Mxil, a Myc antagonist, suppresses proliferation of DU145 human prostate cells, PROSTATE, 47(3), 2001, pp. 194-204
Authors:
Berruti, A
Dogliotti, L
Mosca, A
Tarabuzzi, R
Torta, M
Mari, M
Gorzegno, G
Fontana, D
Angeli, A
Citation: A. Berruti et al., Effects of the somatostatin analog lanreotide on the circulating levels ofchromogranin-A, prostate-specific antigen, and insulin-like growth factor-I in advanced prostate cancer patients, PROSTATE, 47(3), 2001, pp. 205-211
Authors:
Lin, DL
Tarnowski, CP
Zhang, J
Dai, JL
Rohn, E
Patel, AH
Morris, MD
Keller, ET
Citation: Dl. Lin et al., Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro, PROSTATE, 47(3), 2001, pp. 212-221
Authors:
McNeel, DG
Nguyen, LD
Ellis, WJ
Higano, CS
Lange, PH
Disis, ML
Citation: Dg. Mcneel et al., Naturally occurring prostate cancer antigen-specific T cell responses of aTh1 phenotype can be detected in patients with prostate cancer, PROSTATE, 47(3), 2001, pp. 222-229
Authors:
Lein, M
Jung, K
Hammerer, P
Graefen, M
Semjonow, A
Stieber, P
Ossendorf, M
Luboldt, HJ
Brux, B
Stephan, C
Schnorr, D
Loening, SA
Citation: M. Lein et al., A Multicenter Clinical Trial on the use of alpha(1)-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis, PROSTATE, 47(2), 2001, pp. 77-84
Authors:
Takahashi, H
Fukutome, K
Watanabe, M
Furusato, M
Shiraishi, T
Ito, H
Suzuki, H
Ikawa, S
Hano, H
Citation: H. Takahashi et al., Mutation analysis of the p51 gene and correlation between p53, p73, and p51 expressions in prostatic carcinoma, PROSTATE, 47(2), 2001, pp. 85-90
Authors:
Schmidt, U
Fiedler, U
Pilarsky, CP
Ehlers, W
Fussel, S
Haase, M
Faller, G
Sauter, G
Wirth, MP
Citation: U. Schmidt et al., Identification of a novel gene on chromosome 13 between BRCA-2 and RB-1, PROSTATE, 47(2), 2001, pp. 91-101
Authors:
Pizer, ES
Pflug, BR
Bova, GS
Han, WF
Udan, MS
Nelson, JB
Citation: Es. Pizer et al., Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression, PROSTATE, 47(2), 2001, pp. 102-110
Authors:
Djavan, B
Mazal, P
Zlotta, A
Wammack, R
Ravery, V
Remzi, M
Susani, M
Borkowski, A
Hruby, S
Boccon-Gibod, L
Schulman, CC
Marberger, M
Citation: B. Djavan et al., Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European Prostate Cancer Detection Study, PROSTATE, 47(2), 2001, pp. 111-117
Authors:
Kusaka, N
Nasu, Y
Arata, R
Saika, T
Tsushima, T
Kraaij, R
Bangma, CH
Kumon, H
Citation: N. Kusaka et al., Transrectal ultrasound for monitoring murine orthotopic prostate tumor, PROSTATE, 47(2), 2001, pp. 118-124
Authors:
Liu, XF
Olsson, P
Wolfgang, CD
Bera, TK
Duray, P
Lee, B
Pastan, I
Citation: Xf. Liu et al., PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon, PROSTATE, 47(2), 2001, pp. 125-131
Authors:
Chetcuti, A
Margan, S
Mann, S
Russell, P
Handelsman, D
Rogers, J
Dong, QH
Citation: A. Chetcuti et al., Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array, PROSTATE, 47(2), 2001, pp. 132-140
Authors:
Webber, MM
Quader, STA
Kleinman, HK
Bello-DeOcampo, D
Storto, PD
Bice, G
DeMendonca-Calaca, W
Williams, DE
Citation: Mm. Webber et al., Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression, PROSTATE, 47(1), 2001, pp. 1-13
Authors:
Bjork, T
Schalken, J
Wittjes, W
Ljungberg, B
Lilja, H
Citation: T. Bjork et al., Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, andhuman glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues, PROSTATE, 47(1), 2001, pp. 14-20
Authors:
Wang, L
Liu, BL
Schmidt, M
Lu, Y
Wels, W
Fan, Z
Citation: L. Wang et al., Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells, PROSTATE, 47(1), 2001, pp. 21-28